2023 American Society of Clinical Oncology (ASCO) Annual Meeting – June 2-6, 2023 / Chicago, IL and Virtual
Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Long-Term Safety of Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma in the JAVELIN Bladder 100 Trial (includes PLS)
Bellmunt | Poster #4516
Avelumab as Second-Line or Later Treatment in Patients With Metastatic Merkel Cell Carcinoma: Analysis of Real-World Outcomes in France Using the CARADERM Registry and the French National Healthcare Database
Blom | Poster #9537
Retrospective Clinical Analysis of Circulating Tumor DNA (ctDNA)-Based Molecular Response (MR) and Baseline Blood-Based Tumor Mutational Burden (bTMB) for Monitoring Response in Phase 3 Trial of Bintrafusp Alfa vs Pembrolizumab Treatment of Non-Small Cell Lung Cancer (NSCLC)
Feng | Poster #9088
XRay Vision: A Phase 3 Study of Xevinapant Plus Radiotherapy (RT) for High-Risk, Cisplatin-Ineligible Patients With Resected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN) (includes PLS)
Ferris | Poster #6101
Patients With EGFR-Mutant MET-Altered NSCLC Receiving Tepotinib With an EGFR Tyrosine Kinase Inhibitor (TKI): A Case Series
Le | Poster #9070
Real-World Response Rates and Outcomes of Patients Treated With First-Line Platinum-Based Chemotherapy in Advanced Urothelial Cancer
Moon | Poster #4567
Long-Term Outcomes of Tepotinib in Patients With MET Exon 14 Skipping NSCLC From the VISION Study
Paik | Poster #9060
Estimated Net Benefit of Avelumab + Best Supportive Care (BSC) vs BSC Alone for Patients With Advanced Urothelial Carcinoma (aUC) Using a Quality-Adjusted Time Without Cancer Symptoms or Toxicity (Q-TWiST) Analysis (includes PLS)
Powles | Poster #4515
Tepotinib + Osimertinib for EGFR Mutant (EGFRm) NSCLC With MET Amplification (METamp) After First-Line (1L) Osimertinib
Tan | Poster #9021
Clinical Outcomes Among Patients With Advanced Non-Small Cell Lung Cancer Who Received Targeted Therapy in a Real-World Setting
Yang | Poster #9051
Effect of Extended Treatment With IAP Inhibitor Xevinapant Post Radiotherapy on Efficacy and the Tumor Microenvironment in Preclinical Models
Yeung | Poster #6027
Detection of MET Amplification (METamp) in Patients With EGFR Mutant (m) NSCLC After First-Line (1L) Osimertinib
Yu | Poster #9074
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the website and to manage our corporate commercial objectives, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide which categories you would like to permit. Please note that depending on the settings you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy.
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
In order to continuously improve our website, we anonymously track data for statistical and analytical purposes. With these cookies we can, for example, track the number of visits or the impact of specific pages of our web presence and therefore optimize our content.
These cookies allow us to provide more comfort for you. For example, previously searched products or services can be reloaded again after revisiting our website and you won’t need to enter all the details again. We can also detect if you need assistance with using our website and therefore offer you direct customer support.
These cookies are used to display personalized content matching your interests. We can display personalized and relevant services to ensure you are always up to date on related offers.
Help us direct you to the right information by selecting one of the following options: